Stockscreener 앱 받기
3.59
3.49%
-0.13
시간 외 거래:
3.63
0.04
+1.11%
전일 마감가:
$3.72
열려 있는:
$3.71
하루 거래량:
3.44M
Relative Volume:
1.64
시가총액:
$1.02B
수익:
-
순이익/손실:
$-125.04M
주가수익비율:
-4.378
EPS:
-0.82
순현금흐름:
$-122.99M
1주 성능:
+3.16%
1개월 성능:
+24.22%
6개월 성능:
+147.59%
1년 성능:
+32.96%
1일 변동 폭
$3.555
$3.745
1주일 범위
$3.39
$3.77
52주 변동 폭
$1.01
$3.80
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
3115 MERRYFIELD ROW, SAN DIEGO
ERAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
3.59 | 1.06B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Erasca (NASDAQ:ERAS) Trading Up 4.1% – Should You Buy? - Defense World
Aug Spikes: How Erasca Inc stock responds to policy changesJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - moha.gov.vn
Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
Did Index Inclusion and New RAS Patent Just Shift Erasca's (ERAS) Investment Narrative? - simplywall.st
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Treasury Yields: Is Erasca Inc stock a buy on dipsWeekly Profit Summary & AI Powered Market Entry Strategies - moha.gov.vn
Why Erasca Inc. stock could be next big winnerWeekly Loss Report & Stock Portfolio Risk Management - Улправда
Will Erasca Inc. stock remain a Wall Street favoritePortfolio Update Summary & Risk Controlled Swing Trade Alerts - Улправда
Buyback Watch: Is Erasca Inc. stock a buy on dipsMarket Activity Summary & Daily Chart Pattern Signals - DonanımHaber
Aug Weekly: How Erasca Inc. stock responds to policy changesJuly 2025 Momentum & Free Long-Term Investment Growth Plans - DonanımHaber
Momentum Shift: Why Erasca Inc. stock could be next big winner2025 Geopolitical Influence & Comprehensive Market Scan Reports - Улправда
Erasca (ERAS) Valuation Check After ERAS-0015 Patent Extension and New Chief Scientific Officer Appointment - simplywall.st
Erasca Inc stock hits 52-week high at $3.68 - Investing.com India
Shareholder Erasca Foundation Files To Sell 8,333 Of Erasca Inc [ERAS] - TradingView — Track All Markets
Erasca Inc stock hits 52-week high at $3.68 By Investing.com - Investing.com Nigeria
Erasca (ERAS) Extends ERAS-0015 Patent to 2043 and Strengthens RAS Pipeline Momentum - simplywall.st
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Erasca price target raised to $5 from $4 at Mizuho - MSN
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - MSN
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Erasca, Inc Secures U.S. Patent Protection Through 2043 for ERAS-0015 - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Mizuho raises Erasca stock price target to $5 on RAS space optimism By Investing.com - Investing.com South Africa
Mizuho Raises Price Target on Erasca to $5 From $4, Keeps Outperform Rating - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Hold" by Analysts - MarketBeat
Affinity Asset Advisors LLC Grows Stock Holdings in Erasca, Inc. $ERAS - Defense World
Will Erasca Inc. stock outperform international peers2025 Top Gainers & Fast Gaining Stock Reports - Newser
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Moving Averages: Why Erasca Inc. stock could be next big winnerInsider Buying & Momentum Based Trading Signals - moha.gov.vn
Unusually active option classes on open October 8th - MSN
Erasca to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
Adversity is less terrifying than hope: Erasca Inc (ERAS) - Setenews
Understanding Erasca Inc.’s price movementPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Will Erasca Inc. stock benefit from automation2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Erasca Inc. stock chart pattern explainedJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Erasca Inc. stock remains on watchlistsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):